{"id":"aromatase","name":"Aromatase (CYP19A1)","symbol":"CYP19A1","route":"/targets/aromatase/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2594","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000137869","uniprot":"https://www.uniprot.org/uniprotkb/P11511/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P11511","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1978","open-targets":"https://platform.opentargets.org/target/ENSG00000137869","civic":"https://civicdb.org/genes/1588/summary","oncokb":"https://www.oncokb.org/gene/CYP19A1","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CYP19A1","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=CYP19A1","depmap":"https://depmap.org/portal/gene/CYP19A1?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000137869-CYP19A1","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/1588","omim":"https://www.omim.org/entry/107910"}],"products":[{"id":"aminoglutethimide","name":"Aminoglutethimide","status":"historic","modality":"Oral steroidogenesis inhibitor","route":"/drugs/aminoglutethimide/"},{"id":"anastrozole","name":"Anastrozole","status":"approved","modality":"Oral non-steroidal aromatase inhibitor","route":"/drugs/anastrozole/"},{"id":"formestane","name":"Formestane","status":"historic","modality":"Steroidal aromatase inactivator, fortnightly intramuscular injection","route":"/drugs/formestane/"}],"trials":[{"id":"nct02763566","name":"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer","nct":"NCT02763566","phase":"3","status":"active"},{"id":"ibis-ii","name":"IBIS-II (International Breast Intervention Study II)","nct":"ISRCTN31488319","phase":"3","status":"positive"},{"id":"nct04711252","name":"A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease","nct":"NCT04711252","phase":"3","status":"active"},{"id":"nct05257395","name":"A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer","nct":"NCT05257395","phase":"3","status":"active"},{"id":"nct00006371","name":"A Phase II Trial of Early Medical Adrenalectomy for \"D0.5\" Prostate Cancer","nct":"NCT00006371","phase":"2"}],"pathways":[],"companies":["astrazeneca"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}